CADL insider transactions
Candel Therapeutics Inc. (CADL) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for CADL
- SEC Form 4 filed by Manning Paul B4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Papa Joseph C4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Loggia Nicoletta4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Technology Officer Tyagarajan Seshu4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Nichols William Garrett4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Schoch Charles4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Tak Paul Peter4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Barone Francesca4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Medical Officer Nichols William Garrett exercised 937 shares at a strike of $1.29 and sold $6,540 worth of shares (937 units at $6.98) (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Medical Officer Nichols William Garrett exercised 781 shares at a strike of $1.29 and sold $3,936 worth of shares (781 units at $5.04) (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Director Manning Paul B was granted 1,070,663 shares (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Executive Officer Tak Paul Peter was granted 42,826 shares, increasing direct ownership by 19% to 268,566 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Technology Officer Tyagarajan Seshu was granted 5,353 shares, increasing direct ownership by 6% to 90,865 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Director Martell Christopher was granted 111,349 shares (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Director Papa Joseph C was granted 64,239 shares (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Director Loggia Nicoletta was granted 2,141 shares (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Financial Officer Schoch Charles was granted 5,353 shares, increasing direct ownership by 14% to 43,391 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Director Nabel Gary J. was granted 5,353 shares (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Scientific Officer Barone Francesca was granted 4,282 shares, increasing direct ownership by 4% to 100,809 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Schoch Charles4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Director Benz Edward J. Jr4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Director Gaeta Renee4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Director Loggia Nicoletta4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Director Manning Paul B4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Director Martell Christopher4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Director Nabel Gary J.4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Director Nguyen Diem4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Director Papa Joseph C4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Director Radhakrishnan Maha4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 3 filed by new insider Radhakrishnan Maha3 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Scientific Officer Barone Francesca exercised 18,000 shares at a strike of $1.55 and sold $281,673 worth of shares (32,146 units at $8.76), decreasing direct ownership by 13% to 96,527 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Medical Officer Nichols William Garrett exercised 18,489 shares at a strike of $1.90 and sold $396,995 worth of shares (45,316 units at $8.76), decreasing direct ownership by 34% to 52,493 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Executive Officer Tak Paul Peter sold $229,624 worth of shares (26,172 units at $8.77), decreasing direct ownership by 10% to 225,740 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Amendment: Chief Technology Officer Tyagarajan Seshu exercised 20,000 shares at a strike of $1.29 and sold $275,947 worth of shares (31,278 units at $8.82), decreasing direct ownership by 12% to 85,512 units (SEC Form 4)4/A - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Technology Officer Tyagarajan Seshu sold $275,947 worth of shares (31,278 units at $8.82), decreasing direct ownership by 27% to 85,512 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Officer Schoch Charles sold $44,169 worth of shares (5,000 units at $8.83), decreasing direct ownership by 12% to 38,038 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Large owner Aguilar-Cordova Estuardo returned $254,403 worth of CADL to the company (21,165 units at $12.02), decreasing direct ownership by 6% to 162,929 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Officer Schoch Charles4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Nichols William Garrett4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Barone Francesca4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Tak Paul Peter4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SEC Form 4 filed by Chief Technology Officer Tyagarajan Seshu4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Large owner Aguilar-Cordova Estuardo returned $269,794 worth of CADL to the company (31,335 units at $8.61), decreasing direct ownership by 34% to 60,000 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Technology Officer Tyagarajan Seshu sold $103,476 worth of shares (14,322 units at $7.22), decreasing direct ownership by 13% to 96,790 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Officer Schoch Charles sold $68,717 worth of shares (9,511 units at $7.22), decreasing direct ownership by 18% to 43,038 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Scientific Officer Barone Francesca sold $97,783 worth of shares (13,534 units at $7.22), decreasing direct ownership by 11% to 110,673 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Executive Officer Tak Paul Peter sold $156,811 worth of shares (21,704 units at $7.22), decreasing direct ownership by 8% to 251,912 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Medical Officer Nichols William Garrett sold $75,342 worth of shares (10,428 units at $7.23), decreasing direct ownership by 12% to 79,320 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Officer Schoch Charles sold $81,944 worth of shares (9,971 units at $8.22), decreasing direct ownership by 16% to 52,549 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Technology Officer Tyagarajan Seshu sold $119,534 worth of shares (14,545 units at $8.22), decreasing direct ownership by 12% to 111,112 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Scientific Officer Barone Francesca sold $112,367 worth of shares (13,673 units at $8.22), decreasing direct ownership by 10% to 124,207 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Executive Officer Tak Paul Peter sold $173,996 worth of shares (21,172 units at $8.22), decreasing direct ownership by 7% to 273,616 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Medical Officer Nichols William Garrett sold $88,749 worth of shares (10,799 units at $8.22), decreasing direct ownership by 11% to 89,748 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Large owner Aguilar-Cordova Estuardo returned $1,786,000 worth of CADL to the company (200,000 units at $8.93), decreasing direct ownership by 37% to 173,512 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Large owner Aguilar-Cordova Estuardo returned $3,093,000 worth of CADL to the company (350,000 units at $8.84), decreasing direct ownership by 42% to 273,512 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Director Manning Paul B bought $7,500,000 worth of shares (1,250,000 units at $6.00) (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Large owner Aguilar-Cordova Estuardo returned $7,428,000 worth of CADL to the company (800,000 units at $9.28), decreasing direct ownership by 46% to 473,512 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Large owner Aguilar-Cordova Estuardo returned $289,600 worth of CADL to the company (60,000 units at $4.83), decreasing direct ownership by 40% to 91,335 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- Chief Technology Officer Tyagarajan Seshu sold $92,898 worth of shares (20,392 units at $4.56), decreasing direct ownership by 14% to 125,657 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)